Materials and instruments
General chemicals were of the best grade available, supplied by Tokyo Chemical Industries, Wako Pure Chemical, Aldrich Chemical Co., Watanabe Chemical Industries, NOF Corporation, and Novabiochem. They were used without further purification. Sepharose TM CL-4B resin was purchased from Amersham Biosciences. LF-1 LiposoFast apparatus and polycarbonate membrane filters (100 nm) were purchased from Avestin, Inc.
Mass spectra were taken on a Waters LCT-Premier XE for ESI, and a Bruker UltraFlexIII for MALDI-LIFT-TOF/TOF MS. Fluorescence spectra were measured using a Hitachi F4500 spectrometer. Slit width 5.0 nm for both excitation and emission. The photomultiplier voltage was 700 V. Fluorescence intensity was measured using a Perkin-Elmer 1420 ARVO MX-light microplate reader. High-performance liquid chromatography (HPLC) analyses were performed with an Inertsil ODS-3 column (4.6 mm × 250 mm (for analysis) or 10.0 mm × 250 mm (for purification), GL-Science, Inc.), and the absorbance at 215 nm was monitored. UV-vis absorption spectra were obtained with a Shimadzu UV-2450 spectrophotometer.
CD spectra were obtained with a JASCO J-820 CD spectrometer. Dynamic light scattering (DLS) for size distribution was recorded on a Horiba nano Partica SZ-100.
Recombinat human caspase-3 was purchased from Enzo Life Sciences (Cat. BML-SE169). Calf intestinal alkaline phosphatase (ALP) (Cat. #: M0290S), and recombinant protein phosphatase 1 (PP1) (330 a.a. catalytic subunit of the ±-isoform of type 1 protein phosphatase from rabbit skeletal muscle, Cat. #: P0754S) were purchased from New England Biolabs.
Recombinant PTP1B (321 a.a., Cat. #: PTB2001) was purchased from ATGen. Secreted alkaline phosphatase (SEAP) expression plasmid (pSF-CMV-SEAP) was purchased from Oxford Genetics. Culture plates were purchased from PerkinElmer, and Dulbecco's minimal essential medium (DMEM), fetal bovine serum (FBS), trypsin, and Lipofectamine 3000 were purchased from Invitrogen. The enzyme activities are defined as follows.
S1
Caspase-3 : 1 U = 1 pmol min -1 using Ac-DEVD-pNA (200 µM) as substrate at 30°C ALP : 1 U = 1 µmol min -1 using p-nitrophenyl phosphate (50 mM) as substrate at 37°C PP1 : 1 U = 1 nmol min -1 using p-nitrophenyl phosphate (50 mM) as substrate at 37°C PTP1B : 1 U = 1 nmol min -1 using p-nitrophenyl phosphate (10 mM) as substrate at 37°C SEAP : 1 U = 1 µmol min -1 using p-nitrophenyl phosphate (11 mM) as substrate in 0.97M diethanolamine (pH 9.8) containing 0.5 mM Mg 2+ at 37°C
Synthesis of peptides
General procedure All peptides were synthesized by solid-phase peptide synthesis using Rink Amide MBHA resin.
According to the general Fmoc peptide chemistry, the Fmoc-protected amino acids were successively attached at RT. Then, the peptide was deprotected and cleaved from the resin using trifluoroacetic acid/water/triisopropylsilane/1,2-ethanedithiol (TFA/H2O/TIS/EDT) = (94/2.5/1.0/2.5 (v/v/v/v)). Then, the solvent was removed under Ar atmosphere, and cold ether was added. The precipitate was collected using centrifugation. The final product was purified by reversed-phase HPLC to yield the pure peptide. 
STL1

Preparation of LUVs including CF
DOPC (4 mg) and DOPG-Na (4 mg) (Chart S1) were dissolved in CHCl3 (800 µL). The solvent was then removed under reduced pressure by rotary evaporation under Ar atmosphere, leaving a thin lipid film at the bottom of the flask, which was dried overnight in vacuo. For membrane-damaging activity assay, the lipid films were hydrated in 1 mL of aqueous solution including 50 mM 5,6-carboxyfluorescein (CF, dissolved with 2 eq. NaOH) and 100 mM NaCl (100 mM), and the resulting dispersion was vortexed extensively to form multilamellar vesicle (MLV). The suspension was extruded 31 cycles through polycarbonate membranes (pore diameter: 100 nm) using a LF-1 LiposoFast apparatus. The unencapsulated fluorophore was then separated from the fluorophore-loaded liposomes by size exclusion chromatography with a Sepharose TM CL-4B column pre-conditioned with 10 mM HEPES buffer (pH 7.4) containing 150 mM NaCl, 1 mM EDTA. The formation of LUVs was confirmed by DLS. The phospholipid content of liposome was determined by Stewart (ammonium ferrothiocyanate) assay as described elsewhere.
S2
For LUVs used in CD analysis, the lipid films were hydrated in 1 mL of 10 mM sodium phosphate buffer (pH 7.4) solution including 150 mM NaCl. The dispersion was extensively vortexed, and the resulting MLV suspension was extruded 31 cycles through a membrane (pore diameter: 100 nm) using a LF-1 LiposoFast apparatus.
Measurement of CD spectra
The assay buffer for CD analysis was 10 mM sodium phosphate buffer (pH 7.4) containing 150 mM NaCl. Each peptide and LUVs were mixed in the assay buffer, and the CD spectra of peptides (50 µM 
Cell culture
HEK293T cells were cultured with 10% FBS in DMEM in a humidified atmosphere with 5% CO2 at 37 °C. Then the cells were trypsinized and resuspended in culture medium to a final concentration of 5 × 10 4 cells/ well. 100 µL cell suspension was added to a well of a black 96 well culture plate and incubated for 24 h. Then, the cells were transfected with a plasmid encoding SEAP by using Lipofectamine 3000. After 6 h, the culture medium was replaced with DMEM (phenol red (−), FBS (−), antibiotics (−)), and incubated for 36 h. The half volume of culture medium was sampled for quantification of SEAP activity, S3 and the cells were used for enzyme-triggered compound release experiments.
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